Abstract
The efficacy of lomefloxacin given at 400 mg once daily for 14 days compared with that of trimethoprim-sulfamethoxazole at 160 and 800 mg, respectively, given twice daily for 14 days in the treatment of symptomatic complicated urinary tract infections was studied in a prospective, randomized, single-blind multicenter study. A total of 133 subjects presenting with signs and symptoms of urinary tract infection and an underlying abnormality consistent with complicated urinary tract infection were enrolled in the study. Bacteriologic cure was significantly better in 68 subjects randomized to lomefloxacin than in 65 subjects randomized to trimethoprim-sulfamethoxazole at short-term follow-up (88 versus 52%; 95% confidence intervals [CIs] 77 and 94% and 39 and 65%, respectively) this difference was no longer significant at long-term follow-up (64 versus 47%; CIs, 52 and 75% and 32 and 57%, respectively). Clinical outcomes were similar for both therapeutic regimens at short- and long-term follow-ups. The organisms that infected the subjects pretherapy were more frequently resistant to trimethoprim-sulfamethoxazole, and drug therapy was discontinued more frequently in subjects treated with trimethoprim-sulfamethoxazole because of adverse antimicrobial effects. In secondary analyses, outcomes did not differ with age or underlying genitourinary abnormality.(ABSTRACT TRUNCATED AT 250 WORDS)
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cox C. E. A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections. Am J Med. 1992 Apr 6;92(4A):82S–86S. doi: 10.1016/0002-9343(92)90315-3. [DOI] [PubMed] [Google Scholar]
- Mohler J. L., Cowen D. L., Flanigan R. C. Suppression and treatment of urinary tract infection in patients with an intermittently catheterized neurogenic bladder. J Urol. 1987 Aug;138(2):336–340. doi: 10.1016/s0022-5347(17)43138-7. [DOI] [PubMed] [Google Scholar]
- Naber K. G. Use of quinolones in urinary tract infections and prostatitis. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S1321–S1337. doi: 10.1093/clinids/11.supplement_5.s1321. [DOI] [PubMed] [Google Scholar]
- Rubin R. H., Shapiro E. D., Andriole V. T., Davis R. J., Stamm W. E. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992 Nov;15 (Suppl 1):S216–S227. doi: 10.1093/clind/15.supplement_1.s216. [DOI] [PubMed] [Google Scholar]
- Schaeffer A. J., Anderson R. U. Efficacy and tolerability of norfloxacin vs. ciprofloxacin in complicated urinary tract infection. Urology. 1992 Nov;40(5):446–449. doi: 10.1016/0090-4295(92)90461-5. [DOI] [PubMed] [Google Scholar]
- Schentag J. J., Goss T. F. Quinolone pharmacokinetics in the elderly. Am J Med. 1992 Apr 6;92(4A):33S–37S. doi: 10.1016/0002-9343(92)90305-u. [DOI] [PubMed] [Google Scholar]
- Stone J. W., Andrews J. M., Ashby J. P., Griggs D., Wise R. Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother. 1988 Oct;32(10):1508–1510. doi: 10.1128/aac.32.10.1508. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wise R., Andrews J. M., Ashby J. P., Matthews R. S. In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents. Antimicrob Agents Chemother. 1988 May;32(5):617–622. doi: 10.1128/aac.32.5.617. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wolfson J. S., Hooper D. C. Bacterial resistance to quinolones: mechanisms and clinical importance. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S960–S968. doi: 10.1093/clinids/11.supplement_5.s960. [DOI] [PubMed] [Google Scholar]